Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-23 Monoclonal Antibody in Inflammatory Bowel Disease
NCT07216014Phase 4Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in Crohn's disease and ulcerative colitis (UC), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Steroid-Free Clinical Remission. Started Dec 2025; status: recruiting.
02
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07216014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216014.